ALMS
Alumis Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-20/100
Last price
7.09
▲ 0.25 (3.71%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
6.84
Prev close
6.84
Day high
6.95
Day low
6.65
Volume
1.75M
Market cap
$896.99M
P/E (TTM)
—
52W range
4.08 – 31.35
Day trading desk
Gap from prior close
-0.00%
Prior close 6.84
VWAP
6.87
+3.24% from price
Relative volume
1.12×
Normal
Session range
6.75%
6.64 – 7.09
Position in range
100%
Near session high
ATR (14D)
0.41
5.75% of price
Prior day high
7.17
PDH
Prior day low
6.78
PDL
Bid / ask spread
—
Quote not published
Session volume
2.77M
Avg 2.46M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.94%
-6.9%
1M
-37.57%
-38.7%
3M
-76.70%
-81.2%
6M
-68.94%
-87.1%
YTD
-29.00%
-43.2%
1Y
+72.39%
+56.0%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ALMS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+920.25K
Net buying
Buy transactions
8
1.04M shares
Sell transactions
8
116.08K shares
Net transactions
+16
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
680.83K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 8, 26 | AKKARAJU SRINIVAS Director |
BUY | 986.72K | $10.73M | Indirect |
| Sep 8, 26 | AKKARAJU SRINIVAS Director |
SELL | 96.13K | $1.01M | Indirect |
| Aug 3, 26 | HARDIMAN ROY CHARLES Officer |
SELL | 2.69K | $70.99K | Direct |
| Aug 3, 26 | SCHROER JOHN R Chief Financial Officer |
SELL | 3.28K | $86.55K | Direct |
| Aug 3, 26 | GOLDSTEIN DAVID M PH.D. Officer |
SELL | 2.60K | $68.46K | Direct |
| Aug 3, 26 | DRAPPA JORN Officer |
SELL | 2.45K | $64.53K | Direct |
| Aug 3, 26 | PANGALI SANAM Officer |
SELL | 1.36K | $35.97K | Direct |
| Aug 3, 26 | BRADLEY MARK CHRISTOPHER Officer |
SELL | 2.57K | $67.82K | Direct |
| Jul 6, 26 | PANGALI SANAM Officer |
SELL | 5.00K | $140.00K | Direct |
| Jul 6, 26 | PANGALI SANAM Officer |
CONVERSION | 5.00K | $25.30K | Direct |
| Jun 30, 26 | YAO ZHENGBIN Director |
STOCK | 3.55K | $0 | Direct |
| Jun 30, 26 | SRIVASTAVA SAPNA Director |
STOCK | 3.55K | $0 | Direct |
| Jun 30, 26 | TETRAULT LYNN A. Director |
STOCK | 3.55K | $0 | Direct |
| Jun 30, 26 | MACHADO PATRICK Director |
STOCK | 3.55K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AKKARAJU SRINIVAS |
Director | — | Purchase |
AYURMAYA CAPITAL MANAGEMENT COMPANY, LP |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
BABLER MARTIN |
Chief Executive Officer | — | Purchase |
BRADLEY MARK CHRISTOPHER |
Officer | 88.58K | Sale |
DRAPPA JORN |
Officer | 56.89K | Sale |
FORESITE CAPITAL MANAGEMENT VI, LLC. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
GOLDSTEIN DAVID M PH.D. |
Officer | 248.20K | Sale |
HARDIMAN ROY CHARLES |
Officer | 214.16K | Sale |
RICHARDSON DERRICK |
Officer | 42.80K | Stock Award(Grant) |
TANANBAUM JAMES B |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Fundamentals
Market cap$896.99M
Enterprise value$431.12M
Revenue (TTM)$7.40M
Gross profit$7.40M
EBITDA$-421.45M
Net income$-438.96M
EPS (TTM)$-3.86
Free cash flow$-208.64M
Total cash$502.29M
Total debt$36.43M
Book value / share$3.52
Shares outstanding129.44M
Float97.18M
Short % of float8.11%
Dividend yield0.00%
Beta (5Y)-0.37
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.41
PEG ratio—
Price / sales—
Price / book1.97
EV / revenue58.28
EV / EBITDA-1.02
Gross margin100.00%
Operating margin-6439.89%
Profit margin0.00%
Return on equity-93.65%
Return on assets-45.34%
Debt / equity8.06
Current ratio6.74
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $24.05M | $0 | $0 | $0 | — |
| Operating revenue | $24.05M | $0 | $0 | $0 | — |
| Research & development | $386.00M | $265.55M | $137.68M | $101.30M | +45.4% |
| Selling, general & admin | $91.86M | $35.20M | $20.50M | $12.55M | +161.0% |
| Total operating expense | $477.85M | $300.75M | $158.17M | $113.85M | +58.9% |
| Operating income | -$453.80M | -$300.75M | -$158.17M | -$113.85M | -50.9% |
| Net interest income | $14.18M | $12.02M | $3.37M | $1.99M | +18.0% |
| Pre-tax income | -$251.89M | -$294.23M | -$154.99M | -$111.93M | +14.4% |
| Tax provision | -$8.56M | $0 | — | — | — |
| Net income | -$243.32M | -$294.23M | -$154.99M | -$111.93M | +17.3% |
| Net income to common | -$243.32M | -$294.23M | -$154.99M | -$111.93M | +17.3% |
| Basic EPS | -2.32 | -10.38 | -2.99 | -2.91 | +77.6% |
| Diluted EPS | -2.32 | -10.38 | -2.99 | -2.91 | +77.6% |
| EBIT | -$453.80M | -$300.75M | -$158.17M | -$113.85M | -50.9% |
| EBITDA | -$450.31M | -$297.60M | -$156.89M | -$113.60M | -51.3% |
| Basic shares | 104.71M | 28.34M | 51.84M | 38.41M | +269.4% |
| Diluted shares | 104.71M | 28.34M | 51.84M | 38.41M | +269.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $89.67M | $169.53M | $46.00M | $25.61M | -47.1% |
| Cash & short-term investments | $308.50M | $288.26M | $48.95M | $92.86M | +7.0% |
| Total current assets | $318.23M | $306.19M | $53.36M | $102.56M | +3.9% |
| Property, plant & equipment | $35.16M | $33.69M | $35.22M | $4.47M | +4.4% |
| Goodwill & intangibles | $50.96M | $0 | — | — | — |
| Total assets | $411.94M | $340.99M | $89.61M | $108.17M | +20.8% |
| Total current liabilities | $73.32M | $50.91M | $20.87M | $13.35M | +44.0% |
| Total debt | $36.91M | $30.72M | $32.58M | $1.78M | +20.2% |
| Total liabilities | $110.64M | $80.89M | $428.87M | $303.41M | +36.8% |
| Retained earnings | -$901.88M | -$658.55M | -$364.32M | -$209.32M | -36.9% |
| Shareholder equity | $301.30M | $260.10M | -$339.26M | -$195.24M | +15.8% |
| Working capital | $244.91M | $255.28M | $32.49M | $89.20M | -4.1% |
| Net tangible assets | $250.34M | $260.10M | -$339.26M | -$195.24M | -3.8% |
| Shares issued | 104.71M | 54.41M | 51.84M | 51.84M | +92.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$243.32M | -$294.23M | -$154.99M | -$111.93M | +17.3% |
| Depreciation & amortisation | $3.50M | $3.15M | $1.28M | $250.00K | +10.9% |
| Stock-based compensation | $43.52M | $19.46M | $8.63M | $5.96M | +123.7% |
| Change in working capital | $17.76M | $14.76M | $12.06M | -$1.92M | +20.3% |
| Operating cash flow | -$369.52M | -$255.08M | -$129.97M | -$107.72M | -44.9% |
| Capital expenditure | -$653.00K | -$1.73M | -$4.50M | -$2.41M | +62.3% |
| Investing cash flow | $287.88M | -$113.79M | $60.47M | -$68.75M | +353.0% |
| Share buybacks | — | — | $0 | — | — |
| Financing cash flow | $2.07M | $492.37M | $89.68M | $101.63M | -99.6% |
| Free cash flow | -$370.18M | -$256.81M | -$134.47M | -$110.13M | -44.1% |
| End cash position | $91.05M | $170.63M | $47.13M | $26.95M | -46.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $1.66M | $1.74M | $1.93M | $2.07M | $2.67M | — | -4.5% |
| Operating revenue | $1.66M | $1.74M | $1.93M | $2.07M | $2.67M | — | -4.5% |
| Research & development | $85.34M | $81.54M | $82.78M | $97.84M | $108.75M | — | +4.7% |
| Selling, general & admin | $23.36M | $18.61M | $15.59M | $19.52M | $34.45M | — | +25.5% |
| Total operating expense | $108.69M | $100.15M | $98.37M | $117.36M | $143.21M | — | +8.5% |
| Operating income | -$107.03M | -$98.41M | -$96.44M | -$115.29M | -$140.54M | — | -8.8% |
| Net interest income | $4.95M | $5.35M | $3.55M | $4.59M | $3.43M | — | -7.5% |
| Pre-tax income | -$143.98M | -$93.05M | -$92.93M | -$110.75M | $50.76M | — | -54.7% |
| Tax provision | -$1.76M | — | $0 | $0 | -$8.56M | — | — |
| Net income | -$142.22M | -$93.05M | -$92.93M | -$110.75M | $59.32M | — | -52.8% |
| Net income to common | -$142.22M | -$93.05M | -$92.93M | -$110.75M | $59.32M | — | -52.8% |
| Basic EPS | -1.11 | -0.74 | — | -1.06 | 0.57 | -1.82 | -49.6% |
| Diluted EPS | -1.11 | -0.74 | — | -1.06 | 0.57 | -1.82 | -49.6% |
| EBIT | -$107.03M | -$98.41M | -$96.44M | -$115.29M | -$140.54M | — | -8.8% |
| EBITDA | -$106.16M | -$97.54M | -$95.58M | -$114.38M | -$139.67M | — | -8.8% |
| Basic shares | 128.51M | 125.05M | — | 104.11M | 104.04M | 54.41M | +2.8% |
| Diluted shares | 128.51M | 125.05M | — | 104.11M | 104.04M | 54.41M | +2.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $63.71M | $63.88M | $89.67M | $65.26M | $151.75M | -0.3% |
| Cash & short-term investments | $502.29M | $522.94M | $308.50M | $377.72M | $486.32M | -3.9% |
| Total current assets | $514.08M | $532.41M | $318.23M | $393.29M | $517.56M | -3.4% |
| Property, plant & equipment | $34.12M | $33.49M | $35.16M | $36.57M | $38.55M | +1.9% |
| Goodwill & intangibles | $9.13M | $50.96M | $50.96M | $50.96M | $50.96M | -82.1% |
| Total assets | $560.62M | $671.59M | $411.94M | $488.01M | $610.92M | -16.5% |
| Total current liabilities | $76.23M | $70.90M | $73.32M | $65.42M | $85.58M | +7.5% |
| Total debt | $36.43M | $35.66M | $36.91M | $37.80M | $38.78M | +2.1% |
| Total liabilities | $108.46M | $104.57M | $110.64M | $103.24M | $125.60M | +3.7% |
| Retained earnings | -$1.14B | -$994.93M | -$901.88M | -$808.95M | -$698.19M | -14.3% |
| Shareholder equity | $452.16M | $567.02M | $301.30M | $384.77M | $485.33M | -20.3% |
| Working capital | $437.85M | $461.50M | $244.91M | $327.87M | $431.98M | -5.1% |
| Net tangible assets | $443.02M | $516.06M | $250.34M | $333.81M | $434.37M | -14.2% |
| Shares issued | 128.51M | 127.23M | 104.71M | 104.36M | 104.04M | +1.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$142.22M | -$93.05M | -$92.93M | -$110.75M | $59.32M | — | -52.8% |
| Depreciation & amortisation | $874.00K | $871.00K | $867.00K | $916.00K | $870.00K | — | +0.3% |
| Stock-based compensation | $14.27M | $12.34M | $8.11M | $9.79M | $18.64M | — | +15.7% |
| Change in working capital | $5.31M | -$6.30M | $12.93M | -$10.20M | $3.54M | — | +184.3% |
| Operating cash flow | -$81.50M | -$87.08M | -$71.91M | -$110.91M | -$106.35M | — | +6.4% |
| Capital expenditure | -$237.00K | -$164.00K | — | — | -$616.00K | -$37.00K | -44.5% |
| Investing cash flow | $68.69M | -$285.69M | $95.01M | $24.04M | $129.40M | — | +124.0% |
| Financing cash flow | $12.63M | $346.99M | $1.32M | $0 | $749.00K | — | -96.4% |
| Free cash flow | -$81.74M | -$87.25M | -$71.91M | -$110.91M | -$106.97M | — | +6.3% |
| End cash position | $65.09M | $65.27M | $91.05M | $66.63M | $153.50M | — | -0.3% |
Options analytics
Put / call volume
0.57
Call-heavy session
Put / call open interest
2.72
Positioning, not flow
Max pain
33.00
+376.2% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
3.82K
Contracts, this expiry
Put volume
2.19K
Contracts, this expiry
Heaviest call OI
32.00
50 contracts
Heaviest put OI
25.00
153 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.71 | -0.79 | -11.3% |
| Mar 2026 | -0.83 | -0.74 | +10.5% |
| Dec 2025 | -0.98 | -0.25 | +74.2% |
| Sep 2025 | -1.00 | -1.06 | -6.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.75 | 3 | $1.69M | -18.3% |
| Next quarter | -0.72 | 3 | $1.69M | -12.5% |
| Current year | -3.32 | 3 | $6.26M | -74.0% |
| Next year | -2.87 | 3 | $24.33M | +288.7% |
Analyst targets & ownership
Mean target$32.13
High target$46.00
Low target$15.00
Implied upside352.88%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy1 / 8
Hold1
Sell / Strong sell0 / 0
Held by insiders0.53%
Held by institutions93.61%
Institutions holding277
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
7.15
-0.79% from price
SMA 20
7.88
-12.02% from price
SMA 50
16.89
-58.96% from price
SMA 100
20.72
-65.77% from price
SMA 200
22.09
-68.63% from price
EMA 12
7.59
-6.55% from price
EMA 26
10.27
-30.94% from price
EMA 50
14.38
-50.66% from price
RSI (14)
21.9
Oversold
MACD (12,26,9)
-2.68
Hist 0.53
ATR (14)
0.41
5.89% of price
Realised vol 30D
244.0%
Annualised
Bollinger upper
9.74
20, 2σ
Bollinger lower
6.01
20, 2σ
50 / 200 cross
Death
16.89 vs 22.09
Trend bias
Below 200
-68.63%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.70
More volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
244.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-77.4%
Peak to trough
Max drawdown 5Y
-78.9%
Peak to trough
ATR 14
0.41
5.89% of price
Beta (reported)
-0.37
5Y monthly, from filing
Short interest
Shares short
6.30M
Prior 5.85M
Change vs prior
+7.6%
Shorts adding
% of float
8.11%
Normal
% of shares out
4.87%
Against total outstanding
Days to cover
1.6
Liquid
Float
97.18M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 3, 26 | Guggenheim | DOWNGRADE | Buy | Neutral |
| Sep 2, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Sep 2, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Sep 2, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Sep 2, 26 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
| Aug 14, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Aug 3, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| May 19, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| May 15, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| May 15, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| May 15, 26 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Mar 30, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-01
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-07-02
Corporate Changes & Voting Matters
8-K · 2026-06-29
Proxy Statements
DEF 14A · 2026-05-18
Corporate Changes & Voting Matters
8-K · 2026-05-14
Corporate Changes & Voting Matters
8-K · 2026-03-30
Headlines
Top Premarket Gainers
MT Newswires · 27d ago
Alumis Insider Bought Shares Worth $10,726,255, According to a Recent SEC Filing
MT Newswires · 27d ago
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population
Insider Monkey · 28d ago
Alumis to Participate in Upcoming September Investor Conferences
GlobeNewswire · 33d ago
Is Alumis (ALMS) Overvalued After Its 121% One Year Return?
Simply Wall St. · 34d ago
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy
Simply Wall St. · 34d ago
Guggenheim Downgrades Alumis to Neutral From Buy
MT Newswires · 34d ago
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair?
Simply Wall St. · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.